Psychopharmacology

Learn more about Alto Neuroscience's ALTO-300, in ongoing phase 2b trials as an adjunct treatment for major depressive disorder.

With MM120 in phase 3 in the MindMed trial, what place do psychedelics hold in psychiatry?

An observational cohort study found patients at less risk of hospitalization for alcohol use disorder when also being treated with a GLP-1 agonist anti-diabetic/obesity agent.

In this CME article, learn more about recent developments with lithium as they relate to renal issues.

Data presented at ACNP meeting demonstrated safety, tolerability, and efficacy for SPN-820 for MDD.

A poster at the ACNP Annual Meeting utilized a novel risk-informed case-control design to improve biomarker differentiation for ADHD.

Check out 2 new psychopharmacology innovations!

Stephanie Gorka, PhD, shared findings at the ACNP Annual Meeting on orexin receptor agonists addressing AUDs.

Previewing the 63rd ACNP Annual Meeting, which is set to highlight the latest research in psychiatry.

In a new study, researchers found the subtype of childhood trauma impacts the effectiveness of antipsychotic medications.

Calling it a barrier to care, FDA committees decide to end clozapine REMS.

There is an accumulating body of evidence that metformin may have benefits in aging beyond its effect on glycemic control.

This article explains the role of medications that have high affinity to block dopamine D4.

New positive results demonstrate the efficacy and safety of lumateperone (Caplyta) 42 mg for the prevention of relapse in adult patients with schizophrenia.

Learn more about a specific subset of mood disorders.

What’s the truth about benzodiazepines?

Although safety and tolerability was positive, ALTO-100 failed to reach primary endpoint in MDD study.

Learn more about the new positive efficacy, safety, tolerability data from the phase 3 SOLARIS trial, which were presented at the 37th Annual European College of Neuropsychopharmacology Congress.

Jelena Kunovac, MD, MS, discusses last week's approval of Cobenfy, an agent with a novel mechanism of action that could revolutionize schizophrenia treatment.

Cobenfy: Only the first in a new upcoming class of antipsychotics.

While there is still a lot to learn about Cobenfy, here's why it marks a historic moment in the treatment of schizophrenia.

The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?

The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years.

Why are experts excited about KarXT, a novel muscarinic acetylcholine receptor agonist that, if approved, is poised to revolutionize schizophrenia treatment?

The PDUFA date for KarXT for schizophrenia is September 26, 2024. Here’s what one expert thinks of this potential treatment.